Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer-Reference-Cited by-同舟云学术

Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer

Published:2019-05-14 Issue:6 Volume:36 Page:
ISSN:1357-0560
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Tanaka Hisashi^ORCID,Taima Kageaki,Itoga Masamichi,Ishioka Yoshiko,Baba Keisuke,Shiratori Toshihiro,Sakamoto Hiroaki,Tsuchiya Junichiro,Nakagawa Hideyuki,Hasegawa Yukihiro,Yasugahira Hideo,Okudera Koichi,Takanashi Shingo,Tasaka Sadatomo

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12032-019-1278-9.pdf

Reference31 articles.

1. Siegel R, Naishadham D, Jemal A. Cancer statistics 2012. CA Cancer J Clin. 2012;62:10–29.

2. Roskoski R Jr. The ErbB/HER family of proteintyrosine kinases and cancer. Pharmacol Res. 2014;79:34–74.

3. Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9:154–62.

4. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–8.

5. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121–8.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis;Journal of Personalized Medicine;2024-07-15

2. EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational study;Respiratory Investigation;2024-03

3. Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?;Translational Lung Cancer Research;2024-02

4. EGFR is a potential dual molecular target for cancer and Alzheimer’s disease;Frontiers in Pharmacology;2023-08-02

5. Rechallenge of afatinib for EGFR-mutated non-small cell lung cancer previously treated with osimertinib: a multicenter phase II trial protocol (REAL study);Translational Lung Cancer Research;2023-06